Biomarker Risk Assessment and Bladder Cancer Detection in a Cohort Exposed to Benzidine

Hemstreet, George P.; Yin, Shu; Ma, Zhenzhong; Bonner, Rebecca B.; Bi, Wenfang; Rao, Jian Yu; Zang, Mengqing; Zheng, Qinlong; Bane, Barbara L.; Asal, Nabih R.; Li, Guilan; Feng, Peng; Hurst, Robert E.; Wang, Wenyu

doi:10.1093/jnci/93.6.427

Cited by 78 publications

(39 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After removal of reviews, meta-analyses, and redundant trials, 20 studies assessable for criteria concerning assay performance and comprising more than 5,000 individuals were identified, forming the basis for this assessment of assay performance [13,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114]. …”

Section: Cell-based Assaysmentioning

confidence: 99%

Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus

et al. 2014

View full text Add to dashboard Cite

Due to the lack of disease-specific symptoms, diagnosis and follow-up of bladder cancer has remained a challenge to the urologic community. Cystoscopy, commonly accepted as a gold standard for the detection of bladder cancer, is invasive and relatively expensive, while urine cytology is of limited value specifically in low-grade disease. Over the last decades, numerous molecular assays for the diagnosis of urothelial cancer have been developed and investigated with regard to their clinical use. However, although all of these assays have been shown to have superior sensitivity as compared to urine cytology, none of them has been included in clinical guidelines. The key reason for this situation is that none of the assays has been included into clinical decision-making so far. We reviewed the current status and performance of modern molecular urine tests following systematic analysis of the value and limitations of commercially available assays. Despite considerable advances in recent years, the authors feel that at this stage the added value of molecular markers for the diagnosis of urothelial tumors has not yet been identified. Current data suggest that some of these markers may have the potential to play a role in screening and surveillance of bladder cancer. Well-designed protocols and prospective, controlled trials will be needed to provide the basis to determine whether integration of molecular markers into clinical decision-making will be of value in the future.

show abstract

Section: Cell-based Assaysmentioning

confidence: 99%

Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus

et al. 2014

View full text Add to dashboard Cite

show abstract

“…6,7 One of the most important classes of bladder carcinogens in tobacco smoking is benzo(a)pyrenes, and they are detoxified by GSTP1,8 which is located on chromosome 11q13.…”

Section: -5mentioning

confidence: 99%

“…[1][2][3][4][5] Tobacco smoking is a major risk factor for bladder cancer and it is responsible for about 45% of all bladder cancers. 6,7 One of the most important classes of bladder carcinogens in tobacco smoking is benzo(a)pyrenes, and they are detoxified by GSTP1, 8 which is located on chromosome 11q13. 2 GST polymorphic variances can affect the function of these enzymes and they have also been shown to be associated with differences in clinical phenotypes.…”

Section: Introductionmentioning

confidence: 99%

Association analysis of glutathione‐S‐transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M‐VAC chemotherapy

Yokomizo¹,

Yamamoto

Tsunoda³

et al. 2007

Int J of Urology

View full text Add to dashboard Cite

Aim: Glutathione-S-transferase P1 (GSTP1) detoxifies a wide range of endogenous and exogenous carcinogens and anticancer agents such as cisplatin and doxorubicin. The aim of this study was to examine the association between GSTP1 polymorphism and both urothelial cancer susceptibility and adverse events of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy in Japanese urothelial cancer patients. Methods: This cohort consisted of 179 urothelial cancer patients and 225 healthy controls matched for age and sex. GSTP1 Ile105Val polymorphism was identified by direct sequencing methods. Furthermore, the association of GSTP1 polymorphism and adverse events of M-VAC chemotherapy was investigated. Results: A similar frequency of GSTP1 Ile105Val allele was observed in the urothelial cancer patients and in the control group. However, when the 46 patients who underwent systemic M-VAC chemotherapy were investigated , significantly more severe toxicity in leukocytopenia (P = 0.044, odds ratio +•, 95% confidence interval 0.9203-+•) and a prolonged duration of G-CSF administration (P = 0.013, odds ratio 8.625, 95% confidence interval 1.390-89.98) were observed in patients with the Val allele in comparison to those with the Ile allele. Conclusions: The GSTP1 Ile105Val polymorphism was not found to be significantly associated with urothelial cancer susceptibility but it may be associated with myelosuppressive adverse events in M-VAC chemotherapy. The 105Val might therefore be a useful marker for predicting myelosuppression in M-VAC chemotherapy.Key words: GSTP1, M-VAC, neutrocytopenia, polymorphism, urothelial cancer. IntroductionGlutathione-S-transferases (GST) are a family of five classes of detoxification enzymes that are involved in the metabolism of a wide variety of potentially carcinogenic compounds and anticancer agents. 1-5Tobacco smoking is a major risk factor for bladder cancer and it is responsible for about 45% of all bladder cancers. 6,7 One of the most important classes of bladder carcinogens in tobacco smoking is benzo(a)pyrenes, and they are detoxified by GSTP1,8 which is located on chromosome 11q13.2 GST polymorphic variances can affect the function of these enzymes and they have also been shown to be associated with differences in clinical phenotypes. A single nucleotide polymorphism (SNP) in the coding sequence at codon 105 (Ile105Val) of GSTP1 was found to result in a reduced enzymatic activity in vitro. 9 It seems reasonable that a decreased detoxification capacity by reduced enzymatic activity may increase susceptibility to cancer.Several studies have examined the GSTP1 Ile105Val polymorphism in oral, breast and prostate cancer susceptibility.3,10-14 However, the findings remain controversial in bladder and urothelial cancer. Some studies reported a positive correlation between this polymorphism and bladder cancer, [15][16][17] while other studies found no correlation between this polymorphism and urothelial cancers. 18 Moreover, meta-analyses on Spanish patients found a significant as...

show abstract

“…Worldwide, approximately 261 000 new cases of bladder cancer are diagnosed each year (Parkin et al, 1999). Tobacco smoking is a major risk factor for bladder cancer and responsible for about 45% of bladder cancers (Parkin et al, 1999;Hemstreet et al, 2001). Compared with non-smokers, smokers have 2 -4-fold higher risk of developing bladder cancer (Hartge et al, 1987;Burch et al, 1989;Clavel et al, 1989;Morrison et al, 1984;Taylor et al, 1998).…”

Section: Bladder Cancermentioning

confidence: 99%

Molecular detection approaches for smoking associated tumors

2002

View full text Add to dashboard Cite

Smoking is directly responsible for approximately 90% of lung cancers and is also strongly associated with cancers of the head and neck, esophagus and urinary bladder. Our growing understanding of the molecular changes that underlie cancer progression has contributed to the development of novel molecular approaches for the detection of cancer. In this study, we review a number of recent studies that have used molecular techniques to detect neoplastic DNA from lung, head and neck, esophagus and bladder cancer. The majority of these approaches are based on polymerase chain reaction (PCR) based assays. These PCR-based techniques can detect a few clonal cancer cells containing a specific DNA mutation, microsatellite alteration, or CpG island methylation among an excess background of normal cells. The ability to accurately detect a small number of malignant cells in a wide range of clinical specimens including sputum, saliva, bronchoalveolar lavage fluid, urine, serum, plasma, or tissue has significant implications for screening high-risk individuals (such as cigarette smokers) for cancer.

show abstract

Biomarker Risk Assessment and Bladder Cancer Detection in a Cohort Exposed to Benzidine

Abstract: Occupationally exposed workers at risk for bladder cancer can be individually stratified, screened, monitored, and diagnosed based on predefined molecular biomarker profiles.

Cited by 78 publications

References 34 publications

Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus

Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus

Association analysis of glutathione‐S‐transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M‐VAC chemotherapy

Molecular detection approaches for smoking associated tumors

Contact Info

Product

Resources

About